Manufacturing

AstraZeneca Job Creation Vaccines U.S. Facilities Trade Astrazeneca

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030

The decision answers potential Trump administration tariffs by bolstering U.S. manufacturing to help meet the company’s goal of half its revenue from America by 2030.